- Home
- MCRI vs KOD Comparison
MCRI vs KOD Comparison
Compare MCRI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | KOD |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 1993 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MCRI | KOD |
|---|---|---|
| Price | $93.96 | $21.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $100.50 | $28.29 |
| AVG Volume (30 Days) | 119.7K | ★ 648.6K |
| Earning Date | 02-04-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 41.41 | N/A |
| EPS | ★ 5.43 | N/A |
| Revenue | ★ $545,125,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $1.80 | N/A |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | ★ 4.39 | N/A |
| 52 Week Low | $69.99 | $1.92 |
| 52 Week High | $113.88 | $31.18 |
Technical Indicators
Market Signals| Indicator | MCRI | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 43.59 |
| Support Level | $93.22 | $21.20 |
| Resistance Level | $101.07 | $23.27 |
| Average True Range (ATR) | 3.14 | 1.98 |
| MACD | 0.38 | -0.22 |
| Stochastic Oscillator | 40.06 | 29.27 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.